Analytical Data
-
Gene name
Apolipoprotein A-V/APOA5
- Application
-
Alternative Names
Apo-A5; APOA-V; APOAV; RAP3; Regeneration-associated protein 3
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8C7G5
-
Expression Region
Arg21~Gly368
-
Molecular Weight
44kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein A-V (APOA5) is a critical protein involved in lipid metabolism and has emerged as a significant factor in regulating plasma triglyceride levels. Understanding the function and mechanisms of APOA5 is essential due to its implications in cardiovascular diseases and disorders related to lipid metabolism. Research has indicated that variations in the APOA5 gene are associated with dyslipidemia and increased risk of atherosclerosis. Recombinant protein technology allows for the production of APOA5, providing valuable insight into its structure-function relationship, potential binding partners, and its role in lipid transport and metabolism. By producing and characterizing recombinant APOA5 protein, researchers aim to unravel its contributions to triglyceride metabolism and to develop therapeutic strategies targeting dyslipidemic conditions. The study of APOA5 and its interactions with lipoproteins may offer new avenues for clinical interventions in managing cardiovascular risk factors, thereby underscoring the significance of this protein in human health.
